联合化疗市场规模、份额和成长分析：按药物、剂量、给药方法、不孕性别和地区划分 - 产业预测，2024-2031 年

联合化疗市场规模将于2022年达到50.7亿美元，从2023年的53.3亿美元成长到2031年的79.2亿美元，在预测期间（2024-2031年）预计复合年增长率为5.08%。

由于多种因素，联合化疗市场正在经历显着成长。癌症发生率的增加、药物配製技术的进步以及易患癌症的老年人口的增加强调了个人化治疗的必要性。然而，市场面临严格的监管标准和与化疗製剂相关的安全问题的挑战，凸显了监管合规性和病人安全的重要性。同时，充满希望的机会也正在出现，包括配方技术的进步和精准医疗策略的更多采用。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 市场生态系统
• Start-Ups分析
• 监管环境
• 创新矩阵
• 重点投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

联合化疗市场：依药物分类

• 市场概况
• 细胞毒性药物
• 荷尔蒙药物
• 免疫调节剂
• 标靶治疗
• 支持治疗药物

联合化疗市场：按剂量

• 市场概况
• 化疗
• 非化疗药物

联合化疗市场：按给药方式

• 市场概况
• 重量式自动混配装置
• 容积式自动配料装置

联合化疗市场：不孕性别

• 市场概况
• 已灭菌
• 非无菌

联合化疗市场：依技术分类

• 市场概况
• 机械臂
• 无机械臂

联合化疗市场：按组合类型

• 市场概况
• 药物成分变化（PIA）
• 目前无法使用的药品製造 (CUPM)
• 药物剂量变更 (PDA)

联合化疗市场：依组合药物类型

• 市场概况
• 药管
• 等盾临
• 麦迪米克斯
• 整合
• 其他的

联合化疗市场：依应用分类

• 市场概况
• 乳癌
• 血癌
• 摄护腺癌
• 消化道癌症
• 呼吸道/肺癌
• 其他的

联合化疗市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Pfizer Inc.（United States）
• Novartis International AG（Switzerland）
• Roche Holding AG（Switzerland）
• Eli Lilly and Company（United States）
• Bristol Myers Squibb Company（United States）
• Merck & Co., Inc.（United States）
• Johnson & Johnson（United States）
• Sanofi SA（France）
• AstraZeneca PLC（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Amgen Inc.（United States）
• Bayer AG（Germany）
• Gilead Sciences, Inc.（United States）
• Celgene Corporation（United States）
• Biogen Inc.（United States）
• Astellas Pharma Inc.（Japan）
• Daiichi Sankyo Company, Limited（Japan）
• Regeneron Pharmaceuticals, Inc.（United States）

Compounding Chemotherapy Market size was valued at USD 5.07 billion in 2022 and is poised to grow from USD 5.33 billion in 2023 to USD 7.92 billion by 2031, growing at a CAGR of 5.08% in the forecast period (2024-2031).

The compounding chemotherapy market is experiencing substantial growth driven by several factors. These include the increasing incidence of cancer, advancements in pharmaceutical compounding technologies, and a growing elderly population more prone to cancer, emphasizing the need for personalized treatment. However, the market encounters challenges such as stringent regulatory standards and safety issues related to chemotherapy compounding, highlighting the critical importance of adherence to regulations and patient safety. On the other hand, promising opportunities are emerging, including ongoing advancements in compounding technologies and the rising adoption of precision medicine strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Compounding Chemotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Compounding Chemotherapy Market Segmental Analysis

Global Compounding Chemotherapy Market is segmented based on drug, dose, delivery method, sterility, and region. Based on drug, the market is segmented into cytotoxic drugs, hormonal agents, immunomodulatory agents, targeted therapies, and supportive care drugs. Based on dose, the market is segmented into Chemotherapeutic and Non-Chemotherapeutics. Based on delivery methods, the market is segmented into gravimetric automated compounding devices and volumetric automated compounding devices. Based on sterlity, the market is segmented into Sterile and Non-Sterile. Based on region, the market is segmented into North America, Euorpe, Asia Pacific, Latin America, Middle East & Africa.

Drivers of the Compounding Chemotherapy Market

The move towards personalized medicine is opening substantial opportunities for the combination therapy market. As healthcare providers increasingly recognize the significance of tailored therapeutic approaches, there has been a significant rise in demand for personalized treatments. Combination therapy is uniquely positioned to capitalize on this trend by offering the flexibility to customize treatments based on patient-specific characteristics. By streamlining custom formulations, these products address a shifting paradigm in chemotherapy healthcare, where personalized approaches are increasingly recognized as crucial for achieving successful outcomes.

Restraints in the Compounding Chemotherapy Market

One of the primary obstacles in the market arises from the absence of standardized practices and formulations. Variations in pharmaceutical compositions and formulations pose challenges regarding the stability and reliability of combination therapeutics. These differences can affect the potency and stability of drugs, potentially resulting in inconsistent clinical outcomes for patients. The lack of a standardized protocol for drug combinations presents a barrier for healthcare professionals, complicating their ability to compare and assess various drug combinations effectively.

Market Trends of the Compounding Chemotherapy Market

Pharmacogenomics explores how an individual's genetic profile influences their response to medications, examining intricate interactions between genetic variations and drug effects. Understanding pharmacokinetics empowers healthcare providers to refine treatment approaches, aiming to enhance outcomes for each patient. Incorporating pharmacotherapeutic insights is especially beneficial in developing combination therapies, allowing drugs to be personalized based on a patient's specific genotype. This personalized approach enables healthcare providers to optimize treatment effectiveness while minimizing the potential for adverse effects.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Compounding Chemotherapy Market by Drug

• Market Overview
• Cytotoxic drugs
• Hormonal agents
• Immunomodulatory agents
• Targeted therapies
• Supportive care drugs

Global Compounding Chemotherapy Market by Dose

• Market Overview
• Chemotherapeutic
• Non-Chemotherapeutics

Global Compounding Chemotherapy Market by Delivery Method

• Market Overview
• Gravimetric Automated Compounding Devices
• Volumetric Automated Compounding Devices

Global Compounding Chemotherapy Market by Sterility

• Market Overview
• Sterile
• Non-Sterile

Global Compounding Chemotherapy Market by Technology

• Market Overview
• Robotic Arms
• Without Robotic Arms

Global Compounding Chemotherapy Market by Compounding Type

• Market Overview
• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)

Global Compounding Chemotherapy Market by Compounder Type

• Market Overview
• Pharmoduct,
• Equashield Pro
• Medimix
• Integra
• Others

Global Compounding Chemotherapy Market by Application

• Market Overview
• Breast Cancer
• Blood Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Respiratory/Lung Cancer
• Others

Global Compounding Chemotherapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments